• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Varian Medical Systems

Varian Medical Systems

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Energy Based Ablation Devices - Global Strategic Business Report 2017 - Research and Markets

    Energy Based Ablation Devices - Global Strategic Business Report 2017 - Research and Markets

  2. Greece’s Darkest Hour Before Its Dawn

    Varian Medical Systems' VAR third-quarter results were in line with our expectations, and we are leaving our fair value estimate unchanged. Overall, revenue increased 7%, and net orders rose 13%, bringing the company's backlog at quarter-end to $1.6 billion. Revenue for the oncology system segment ...

  3. Worldwide Computed Tomography (CT) Markets Opportunity Report 2017 Featuring Analogic, Arineta, Bayer, Carestream Health, GE Healthcare, Hitachi, Philips, Planmed Oy, and Siemens - Research and ...

    Worldwide Computed Tomography (CT) Markets Opportunity Report 2017 Featuring Analogic, Arineta, Bayer, Carestream Health, GE Healthcare, Hitachi, Philips, Planmed Oy, and Siemens - Research and Markets

  4. Safe Stocks for Worried Investors

    The stocks mentioned in this article be holdings in the managed portfolios of Validea Capital Management, a separate asset management firm founded by Validea.com founder John Reese. Validea Capital Management, which an SEC registered investment advisory firm and a separate company from Validea.com, ...

  5. The Middle Ground

    The stocks mentioned in this article be holdings in the managed portfolios of Validea Capital Management, a separate asset management firm founded by Validea.com founder John Reese. Validea Capital Management, which an SEC registered investment advisory firm and a separate company from Validea.com, uses, in part, the strategies discussed in this article to select stocks for its clients.

  6. Research Roundup: Foreign Diversification, Social Comparisons and Consumer Identity

    Varian Medical's VAR third-quarter fiscal 2006 results fall right in line with the seasonal patterns we expected from our current near-term modeling assumptions. The oncology group notched 14% growth, and customer demand continues to reflect a shift toward Varian's next-generation IGRT technology, ...

12

©2017 Morningstar Advisor. All right reserved.